These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1747 related items for PubMed ID: 23627249

  • 1. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K, Neuenschwander PF, Kurdowska AK.
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [Abstract] [Full Text] [Related]

  • 2. The effectiveness of sublingual and topical compounded bioidentical hormone replacement therapy in postmenopausal women: an observational cohort study.
    Ruiz AD, Daniels KR.
    Int J Pharm Compd; 2014; 18(1):70-7. PubMed ID: 24881343
    [Abstract] [Full Text] [Related]

  • 3. Transdermal progesterone: effects on menopausal symptoms and on thrombotic, anticoagulant, and inflammatory factors in postmenopausal women.
    Stephenson K, Neuenschwander PF, Kurdowska AK, Pinson B, Price C.
    Int J Pharm Compd; 2008; 12(4):295-304. PubMed ID: 23969765
    [Abstract] [Full Text] [Related]

  • 4. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S, Zochowska E, Safranow K, Sieja K, Stanosz M.
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [Abstract] [Full Text] [Related]

  • 5. Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women.
    Matthews KA, Wing RR, Kuller LH, Meilahn EN, Plantinga P.
    Arch Intern Med; 1994 Oct 24; 154(20):2349-55. PubMed ID: 7944857
    [Abstract] [Full Text] [Related]

  • 6. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
    Eilertsen AL, Høibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM.
    Maturitas; 2005 Oct 16; 52(2):111-8. PubMed ID: 16186073
    [Abstract] [Full Text] [Related]

  • 7. DHEA, important source of sex steroids in men and even more in women.
    Labrie F.
    Prog Brain Res; 2010 Oct 16; 182():97-148. PubMed ID: 20541662
    [Abstract] [Full Text] [Related]

  • 8. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
    Holtorf K.
    Postgrad Med; 2009 Jan 16; 121(1):73-85. PubMed ID: 19179815
    [Abstract] [Full Text] [Related]

  • 9. Testosterone addition to estrogen therapy - effects on inflammatory markers for cardiovascular disease.
    Kocoska-Maras L, Hirschberg AL, Byström B, Schoultz BV, Rådestad AF.
    Gynecol Endocrinol; 2009 Dec 16; 25(12):823-7. PubMed ID: 19906002
    [Abstract] [Full Text] [Related]

  • 10. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
    Araújo DA, Farias ML, Andrade AT.
    Climacteric; 2002 Sep 16; 5(3):286-92. PubMed ID: 12419087
    [Abstract] [Full Text] [Related]

  • 11. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
    Stomati M, Monteleone P, Casarosa E, Quirici B, Puccetti S, Bernardi F, Genazzani AD, Rovati L, Luisi M, Genazzani AR.
    Gynecol Endocrinol; 2000 Oct 16; 14(5):342-63. PubMed ID: 11109974
    [Abstract] [Full Text] [Related]

  • 12. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N, Genazzani AD, Bernardi F, Casarosa E, Pieri M, Palumbo M, Picciarelli G, Gabbanini M, Luisi M, Genazzani AR.
    Gynecol Endocrinol; 2005 Mar 16; 20(3):144-9. PubMed ID: 16019353
    [Abstract] [Full Text] [Related]

  • 13. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B, Guzic-Salobir B, Sebestjen M, Keber I.
    Menopause; 2006 Mar 16; 13(4):643-50. PubMed ID: 16837886
    [Abstract] [Full Text] [Related]

  • 14. Hormone replacement therapy in postmenopausal women.
    Yasui T, Uemura H, Takikawa M, Irahara M.
    J Med Invest; 2003 Aug 16; 50(3-4):136-45. PubMed ID: 13678382
    [Abstract] [Full Text] [Related]

  • 15. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
    Taner MZ, Ozpolat E, Taskiran C, Onan MA, Gursel T, Karabulut E, Gursoy R, Himmetoglu O.
    Maturitas; 2006 Feb 20; 53(3):267-73. PubMed ID: 15978753
    [Abstract] [Full Text] [Related]

  • 16. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms.
    Adler G, Young D, Galant R, Quinn L, Witchger MS, Maki KC.
    Gynecol Obstet Invest; 2005 Feb 20; 59(4):212-9. PubMed ID: 15753617
    [Abstract] [Full Text] [Related]

  • 17. [Aerodiol: the efficacy and tolerability of intranasal estrogen administration. An overview].
    Genazzani AR, Cappagli B, Ciaponi M.
    Minerva Ginecol; 2003 Jun 20; 55(3):189-200. PubMed ID: 14581864
    [Abstract] [Full Text] [Related]

  • 18. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study.
    Piltonen T, Puurunen J, Hedberg P, Ruokonen A, Mutt SJ, Herzig KH, Nissinen A, Morin-Papunen L, Tapanainen JS.
    Hum Reprod; 2012 Oct 20; 27(10):3046-56. PubMed ID: 22811306
    [Abstract] [Full Text] [Related]

  • 19. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H.
    Climacteric; 2003 May 20; 6 Suppl 1():11-36. PubMed ID: 12945798
    [Abstract] [Full Text] [Related]

  • 20. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
    Krapf JM, Simon JA.
    Maturitas; 2009 Jul 20; 63(3):213-9. PubMed ID: 19487090
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 88.